High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load
- PMID: 31470004
- DOI: 10.1053/j.gastro.2019.08.028
High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load
Abstract
Background & aims: Chronic hepatitis B virus (HBV) infection is a risk factor for hepatocellular carcinoma (HCC). Serum levels of HB core-related antigen (HBcrAg) have been associated with active replication of HBV. We investigated whether HBcrAg levels are associated with development of HCC, especially in patients who do not require antiviral treatment.
Methods: We collected data from 2666 adults positive for hepatitis B surface antigen (HBsAg), infected with HBV genotypes B or C, and without liver cirrhosis, who had long-term follow-up at the National Taiwan University Hospital from 1985 through 2000. None of the patients received antiviral treatment during the follow-up. Baseline levels of HBV DNA, HBsAg, and HBcrAg were determined retrospectively and participants were followed for a mean of 15.95 years. The primary end point was an association between serum level of HBcrAg and HCC development.
Results: HCC developed in 209 patients in the cohort (incidence rate, 4.91 cases/1000 person-years). We found a positive association between baseline level of HBcrAg and HCC development; HBcrAg level was an independent risk factor in multivariable analysis. In the subgroup of hepatitis B e antigen-negative patients with HBV DNA levels from 2000 to 19,999 IU/mL (intermediate viral load [IVL]) and normal levels of alanine aminotransferase, HBcrAg levels of 10 KU/mL or more identified patients at increased risk of HCC (hazard ratio, 6.29; confidence interval, 2.27-17.48). Patients with an IVL and a high level of HBcrAg had a risk for HCC that did not differ significantly from that of patients with a high viral load (≥20,000 IU/mL). Patients with an IVL but a low level of HBcrAg had a low risk of HCC, with an annual incidence rate of 0.10% (95% confidence interval, 0.04%-0.24%).
Conclusions: In a long-term follow-up study of 2666 patients with chronic HBV infection (genotypes B or C), level of HBcrAg is an independent risk factor of HCC. Moreover, HBcrAg level of 10 KU/mL identifies patients with an IVL who are at high risk for HCC.
Keywords: ALT; ERADICATE-B Study; Liver Cancer; Virology.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.Aliment Pharmacol Ther. 2019 Feb;49(4):457-471. doi: 10.1111/apt.15108. Epub 2019 Jan 20. Aliment Pharmacol Ther. 2019. PMID: 30663078
-
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.Gastroenterology. 2012 May;142(5):1140-1149.e3; quiz e13-4. doi: 10.1053/j.gastro.2012.02.007. Epub 2012 Feb 11. Gastroenterology. 2012. PMID: 22333950
-
Natural history of chronic hepatitis B REVEALed.J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. J Gastroenterol Hepatol. 2011. PMID: 21323729 Review.
-
The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.J Gastroenterol. 2017 Mar;52(3):366-375. doi: 10.1007/s00535-016-1240-y. Epub 2016 Jul 15. J Gastroenterol. 2017. PMID: 27422771
-
What can we learn from hepatitis B virus clinical cohorts?Liver Int. 2015 Jan;35 Suppl 1:91-9. doi: 10.1111/liv.12716. Liver Int. 2015. PMID: 25529093 Review.
Cited by
-
HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative.JHEP Rep. 2023 Nov 4;6(1):100956. doi: 10.1016/j.jhepr.2023.100956. eCollection 2024 Jan. JHEP Rep. 2023. PMID: 38089551 Free PMC article.
-
High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.J Gastroenterol. 2023 May;58(5):481-493. doi: 10.1007/s00535-023-01970-3. Epub 2023 Mar 16. J Gastroenterol. 2023. PMID: 36928343 Clinical Trial.
-
Metabolic Syndrome, Nonalcoholic Fatty Liver Disease, and Chronic Hepatitis B: A Narrative Review.Infect Dis Ther. 2023 Jan;12(1):53-66. doi: 10.1007/s40121-022-00725-6. Epub 2022 Nov 27. Infect Dis Ther. 2023. PMID: 36441483 Free PMC article. Review.
-
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection.Clin Mol Hepatol. 2023 Jul;29(3):605-622. doi: 10.3350/cmh.2022.0342. Epub 2023 Feb 15. Clin Mol Hepatol. 2023. PMID: 36788759 Free PMC article. Review.
-
Hepatitis B core-related antigen as a predictive biomarker for recurrence in primary hepatocellular carcinoma: A meta-analysis.World J Gastrointest Oncol. 2025 May 15;17(5):105148. doi: 10.4251/wjgo.v17.i5.105148. World J Gastrointest Oncol. 2025. PMID: 40487961 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical